{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:32:48Z","timestamp":1791894768537,"version":"4.3.4"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring (TDM) involves the measurement of serum drug concentrations to optimize pharmacotherapy. Traditionally, blood pressure measurements alone, and not TDM, have been used to evaluate the antihypertensive drug response. However, approximately 50% of hypertensive patients treated with lifestyle changes and antihypertensive drugs fail to achieve blood pressure control. Serum drug concentration measurements could be useful to select the optimal drugs in adjusted doses and to identify nonadherence. Implementation of TDM in clinical routine for antihypertensive drugs depends on established serum reference ranges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Commonly used antihypertensive drugs were identified based on prescription data. The authors performed a review of authoritative literature on reported serum drug concentrations and calculated expected concentrations from previously reported pharmacokinetic parameters with commonly prescribed daily doses. Finally, serum drug concentrations in samples from patients undergoing antihypertensive treatment were measured.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Serum reference ranges for 24 frequently used antihypertensive drugs were established based on results from 3 approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Serum drug concentration measurements, interpreted in light of the established reference ranges, together with blood pressure measurements and other clinical data, may help identify nonadherent patients and tailor individual antihypertensive treatment when deviant drug responses appear in line with the concept of personalized medicine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000806","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T14:48:34Z","timestamp":1598971714000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Establishing Serum Reference Ranges for Antihypertensive Drugs"],"prefix":"10.1097","volume":"43","author":[{"given":"Stine","family":"Rognstad","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital;"},{"name":"Institute of Clinical Medicine, University of Oslo;"},{"name":"Section of Cardiovascular and Renal Research, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla L.","family":"S\u00f8raas","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular and Renal Research, Oslo University Hospital;"},{"name":"Unit of Environmental and Occupational Medicine, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola U.","family":"Bergland","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo;"},{"name":"Section of Cardiovascular and Renal Research, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aud","family":"H\u00f8ieggen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo;"},{"name":"Section of Cardiovascular and Renal Research, Oslo University Hospital;"},{"name":"Department of Nephrology, Oslo University Hospital, Ullev\u00e5l;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Str\u00f8mmen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Center for Obesity Research, St. Olavs University Hospital, Trondheim, Norway;"},{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Helland","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olavs University Hospital; and"},{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi S.","family":"Opdal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital;"},{"name":"Institute of Clinical Medicine, University of Oslo;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/08037051.2018.1527177","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"27","author":"Williams","year":"2018","journal-title":"Blood Press."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004872-200401000-00003","article-title":"Worldwide prevalence of hypertension: a systematic review","volume":"22","author":"Kearney","year":"2004","journal-title":"J Hypertens."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","article-title":"Selected major risk factors and global and regional burden of disease","volume":"360","author":"Ezzati","year":"2002","journal-title":"Lancet"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08037051.2015.1121706","article-title":"Adherence to medication and drug monitoring in apparent treatment-resistant hypertension","volume":"25","author":"Esk\u00e5s","year":"2016","journal-title":"Blood Press."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/HJH.0000000000001402","article-title":"Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients","volume":"35","author":"Hamdidouche","year":"2017","journal-title":"J Hypertens."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08037051.2014.946787","article-title":"Physician (investigator) inertia in apparent treatment-resistant hypertension\u2014insights from large randomized clinical trials. Lennart Hansson memorial lecture","volume":"24","author":"Kjeldsen","year":"2015","journal-title":"Blood Press."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","article-title":"Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension","volume":"68","author":"Berra","year":"2016","journal-title":"Hypertension"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/hr.2010.183","article-title":"Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy","volume":"34","author":"Ceral","year":"2011","journal-title":"Hypertens Res."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bmj.305.6861.1078","article-title":"ABC of monitoring drug therapy. Measuring plasma drug concentrations","volume":"305","author":"Aronson","year":"1992","journal-title":"BMJ"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpba.2016.07.049","article-title":"UHPLC-MS\/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients","volume":"129","author":"De Nicolo","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jchromb.2006.11.030","article-title":"Simultaneous determination of 6 beta-blockers, 3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhythmic drug in post-mortem whole blood by automated solid phase extraction and liquid chromatography mass spectrometry. Method development and robustness testing by experimental design","volume":"850","author":"Kristoffersen","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchromb.2019.05.013","article-title":"Screening of cardiovascular agents in plasma with LC-MS\/MS: a valuable tool for objective drug adherence assessment","volume":"1121","author":"Punt","year":"2019","journal-title":"J Chromatogr B."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchromb.2018.04.038","article-title":"Quantification of 21 antihypertensive drugs in serum using UHPLC-MS\/MS","volume":"1089","author":"Gundersen","year":"2018","journal-title":"J Chromatogr B."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"15652","DOI":"10.1038\/s41598-019-52164-y","article-title":"Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and beta-blockers\u2014drug classes with low adherence in antihypertensive therapy","volume":"9","author":"Ritscher","year":"2019","journal-title":"Sci Rep."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","article-title":"Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension","volume":"63","author":"Brinker","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2042098612469335","article-title":"The ABCD of clinical pharmacokinetics","volume":"4","author":"Doogue","year":"2013","journal-title":"Ther Adv Drug Saf."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-pharmtox-010510-100502","article-title":"Omics and drug response","volume":"53","author":"Meyer","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-200404000-00010","article-title":"Therapeutic drug monitoring of psychotropic drugs. TDM \u201cnouveau\u201d","volume":"26","author":"Bengtsson","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R24-20250603","first-page":"341","article-title":"Pharmacogenomics and hypertension: current insights","volume":"12","author":"Oliveira-Paula","year":"2019","journal-title":"Pharmgenomics Pers Med."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-med-101712-122545","article-title":"Applied pharmacogenomics in cardiovascular medicine","volume":"65","author":"Weeke","year":"2014","journal-title":"Annu Rev Med."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/15563659709043365","article-title":"Therapeutic, toxic, and lethal concentrations in human fluids of 90 drugs affecting the cardiovascular and hematopoietic systems","volume":"35","author":"Repetto","year":"1997","journal-title":"J Toxicol Clin Toxicol."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/cc11441","article-title":"Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics","volume":"16","author":"Schulz","year":"2012","journal-title":"Crit Care"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/jch.13323","article-title":"Achieving reliable blood pressure measurements in clinical practice: it's time to meet the challenge","volume":"20","author":"O'Brien","year":"2018","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jpba.2017.05.018","article-title":"UHPLC-MS\/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples","volume":"142","author":"De Nicolo","year":"2017","journal-title":"J Pharm Biomed Anal."},{"key":"R40-20250603","first-page":"17","article-title":"A novel \u201cDilute-and-Shoot\u201d liquid chromatography-tandem mass spectrometry method for the screening of antihypertensive drugs in urine","volume":"40","author":"Lawson","year":"2016","journal-title":"J Anal Toxicol."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/jhh.2015.103","article-title":"Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation","volume":"30","author":"Patel","year":"2016","journal-title":"J Hum Hypertens."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/bcp.13706","article-title":"Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence","volume":"84","author":"Avataneo","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/009127000004001202","article-title":"Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol."},{"key":"R44-20250603","first-page":"40","article-title":"Estimated GFR\u2014value or illusion?","volume":"106","author":"Kallner","year":"2009","journal-title":"Lakartidningen"},{"key":"R46-20250603","first-page":"CD007451","article-title":"Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension","volume":"3","author":"Wong","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/js970316d","article-title":"Pharmacokinetics and metabolism of bisoprolol enantiomers in humans","volume":"87","author":"Horikiri","year":"1998","journal-title":"J Pharm Sci."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1067\/mcp.2002.127396","article-title":"Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype","volume":"72","author":"Molden","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cccn.2005.06.013","article-title":"Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem","volume":"362","author":"Yamamoto","year":"2005","journal-title":"Clin Chim Acta."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00498250500158175","article-title":"Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes","volume":"35","author":"Nakashima","year":"2005","journal-title":"Xenobiotica"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cpt1977224385","article-title":"Pharmacokinetics of bendroflumethiazide","volume":"22","author":"Beermann","year":"1977","journal-title":"Clin Pharmacol Ther."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199729002-00002","article-title":"Clinical pharmacokinetics of lercanidipine","volume":"29","author":"Barchielli","year":"1997","journal-title":"Cardiovasc Pharmacol."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2125.1982.tb01991.x","article-title":"Enalapril maleate and a lysine analogue (MK-521): disposition in man","volume":"14","author":"Ulm","year":"1982","journal-title":"Br J Clin Pharmacol."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00193704","article-title":"Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril","volume":"47","author":"van Griensven","year":"1995","journal-title":"Eur J Clin Pharmacol."},{"issue":"suppl 2","key":"R58-20250603","first-page":"S27","article-title":"Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers","volume":"11","author":"van Lier","year":"1997","journal-title":"J Hum Hypertens."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0009-9236(95)90264-3","article-title":"Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly","volume":"57","author":"Oberbauer","year":"1995","journal-title":"Clin Pharmacol Ther."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00542109","article-title":"Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man","volume":"25","author":"Krause","year":"1983","journal-title":"Eur J Clin Pharmacol."},{"key":"R62-20250603","first-page":"154","article-title":"Dose proportionality and pharmacokinetics of eplerenone in healthy Chinese subjects","volume":"66","author":"Chen","year":"2016","journal-title":"Drug Res (Stuttg)."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:18:49Z","timestamp":1748971129000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000806","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-05-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}